Plain-English translation of NCT06777082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers have noticed that a protein called RPL8 is abnormally increased in about 30% of high-grade serous ovarian cancers. This study will examine tumor tissue samples from patients with this type of cancer to understand whether changes in RPL8 could be used to predict how well treatments will work and to help doctors choose the best therapy for each patient.
High-grade serous ovarian cancer is not well understood, and doctors need better ways to predict which patients will respond well to treatment. By studying the role of RPL8 in this cancer, researchers hope to develop new tools that could guide treatment decisions and improve outcomes.
You likely qualify if…
You likely don't qualify if…
Participation involves allowing researchers to use tumor tissue samples that have already been removed during your cancer surgery or that may be collected during future treatment. Researchers will perform laboratory tests on these samples to study the RPL8 protein and compare the results with your medical records and treatment outcomes. There are no additional procedures or visits required beyond your standard cancer care.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy
Enrollment target
~150 participants
Started
March 2024
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lorenzo Montanaro, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.